TFX
Get informed when a big investor buys or sells
+ FollowOvervalued by 4% based on the discounted cash flow analysis.
| Market cap | $5.69 Billion |
|---|---|
| Enterprise Value | $5.57 Billion |
| Dividend Yield | $1.36 (1.06%) |
| Earnings per Share | $-20.3 |
| Beta | 0.82 |
| Outstanding Shares | 44,257,000 |
| P/E Ratio | -5.64 |
|---|---|
| PEG | 5.2 |
| Price to Sales | 3.14 |
| Price to Book Ratio | 1.86 |
| Enterprise Value to Revenue | 3.03 |
| Enterprise Value to EBIT | 48.84 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.06 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4365▼ 67.58% |
|---|---|
| Total Calls | 54,300▲ 35.41% |
| Total Puts | 23,700▼ 46.86% |
Holdings and activity of institutional investors.
| Ownership % | 107.22%▲ 0.55% |
|---|---|
| Total Invested | $5.72B▼ 0.10% |
| Investors Holding | 370▼ 40.00% |
No data
This committee provides the official revenue estimates and technical analysis for all tax legislation, directly influencing corporate tax structures and capital investment credits which are critical for TFX's financial planning and performance.
This committee controls taxation, trade, and entitlement spending (e.g., Medicare). Tax policy directly impacts TFX's profitability, and Medicare pricing and coverage decisions are critical for the medical device industry's revenue streams.
This committee directly allocates federal spending to government agencies and programs, including healthcare initiatives and research (e.g., NIH, VA), which can significantly impact demand and funding for TFX's products.
This committee directly regulates the FDA, which is the primary regulatory body for medical devices, and influences labor laws affecting manufacturing costs, making it highly relevant to TFX.
This committee's funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and the demand for medical devices, making it a significant influence on TFX.